Docoh
Loading...

SRNE Sorrento Therapeutics

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.

Company profile

Ticker
SRNE
Exchange
CEO
Henry Ji
Employees
Incorporated
Location
Fiscal year end
Former names
QUIKBYTE SOFTWARE INC
SEC CIK
IRS number
330344842

SRNE stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

19 Feb 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 56.46M 56.46M 56.46M 56.46M 56.46M 56.46M
Cash burn (monthly) 21.24M 2.03M 23.51M 20.38M 13.62M 13.29M
Cash used (since last report) 75.69M 7.22M 83.78M 72.62M 48.55M 47.38M
Cash remaining -19.22M 49.25M -27.31M -16.15M 7.91M 9.08M
Runway (months of cash) -0.9 24.3 -1.2 -0.8 0.6 0.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Apr 21 Janda Kim Common Stock Sell Dispose S No Yes 6.9742 1,900 13.25K 3,000
12 Apr 21 Janda Kim Common Stock Option exercise Aquire M No Yes 3.5 1,900 6.65K 4,900
12 Apr 21 Janda Kim NQSO Common Stock Option exercise Dispose M No Yes 3.5 1,900 6.65K 0
16 Mar 21 Najjam Asghar Common Stock Grant Aquire A No No 0 56,974 0 56,974
16 Mar 21 Najjam Asghar Stock Option Common Stock Grant Aquire A No No 10.18 100,000 1.02M 100,000
16 Dec 20 Followwill Dorman Common Stock Sell Dispose S No No 7.135 1,000 7.14K 2,130
12 Nov 20 Najjam Asghar Stock Option Common Stock Grant Aquire A No No 6.1 120,000 732K 120,000
11 Nov 20 Followwill Dorman Common Stock By will or laws of descent Aquire W No No 0 1,000 0 3,130
16 Oct 20 Ji Henry NQSO Common Stock Grant Aquire A No No 17.3 24,935,882 431.39M 24,935,882

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

35.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 219 207 +5.8%
Opened positions 57 58 -1.7%
Closed positions 45 34 +32.4%
Increased positions 78 82 -4.9%
Reduced positions 38 40 -5.0%
13F shares
Current Prev Q Change
Total value 848.99M 803.91M +5.6%
Total shares 100.84M 72.08M +39.9%
Total puts 4.61M 3.75M +23.0%
Total calls 4.82M 7.85M -38.6%
Total put/call ratio 1.0 0.5 +100.4%
Largest owners
Shares Value Change
BLK Blackrock 17.62M $120.25M +17.3%
STT State Street 12.68M $86.51M +8.3%
Vanguard 12.31M $84.02M +10.9%
Famous Sino 5.96M $40.71M NEW
China In Shine Investment 4.76M $32.49M NEW
Cormorant Asset Management 4.5M $30.71M -25.0%
Hongguo International 4.07M $27.81M NEW
Geode Capital Management 3.63M $24.78M +15.9%
Asia Pacific MedTech 3.55M $24.22M NEW
Magnum Opus 2 International 3.34M $22.82M NEW
Largest transactions
Shares Bought/sold Change
Famous Sino 5.96M +5.96M NEW
China In Shine Investment 4.76M +4.76M NEW
Hongguo International 4.07M +4.07M NEW
Asia Pacific MedTech 3.55M +3.55M NEW
Magnum Opus 2 International 3.34M +3.34M NEW
BLK Blackrock 17.62M +2.6M +17.3%
Cormorant Asset Management 4.5M -1.5M -25.0%
Vanguard 12.31M +1.21M +10.9%
STT State Street 12.68M +966.6K +8.3%
JPM JPMorgan Chase & Co. 1.4M +824.15K +142.7%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: aberrant, abivertinib, Acalabrutinib, ACEA, acid, adipose, admitted, ADNAB, affinity, AL, albumin, amino, amplification, amyloid, Andrew, anemia, antitumor, antiviral, ANVISA, ARD, Arnaki, ascending, Asghar, Ashgar, assay, atypical, autonomic, bamlanivimab, behavior, Biden, BlackRock, bore, branch, Brazil, Brazilian, Bribery, Brunswick, Bruton, BTK, BTKI, budget, burden, Calquence, Calvo, canine, cardiomyopathy, carryback, chemotherapeutic, chemotherapy, children, circulating, clone, cluster, cohort, colloid, colorimetric, comorbid, composed, concept, constant, constantly, continuum, contributor, Cothera, countermeasure, covalent, covalently, COVI, COVIDTRAPTM, curb, cysteine, Cytimm, daily, DARPA, decoy, deep, defunctionalization, defunctionalize, degradation, deliberate, deployment, developmental, dexamethasone, diagnose, digit, distancing, disulfide, dolastatin, DoseConnect, dozen, drawn, dual, duostatin, dysfunction, dysfunctional, East, eat, edema, eleven, envision, epidermal, Epizyme, Ernst, ESPP, EUA, fluid, founder, furlough, gatekeeper, gearing, globe, Golden, Governor, gradually, grown, gynecological, hamster, hemagglutination, Homeland, honorary, hospital, hospitalization, hospitalized, humoral, hyperinflammatory, hypothesized, IgG, IgM, IM, ImmunoGen, immunomodulatory, impending, inactivated, incubated, infiltrating, influenza, inhibitory, Inline, innate, insoluble, intermittent, intradermal, intramuscular, intranasal, intrapleural, intratumoral, IronShore, irreversible, irreversibly, isothermal, Jeannette, Jefferson, John, jury, Karyopharm, kinase, kit, Lilly, linker, lived, living, loosening, lymphocyte, lymphodepletion, lysosomal, magrolimab, maleate, mark, marker, Markovic, marshalled, Mayo, mcg, mechanistic, Mersana, mesothelioma, Mexico, microenvironment, middle, mild, misfolded, misinterpret, misleading, mission, moiety, monkey, mononuclear, movement, MSC, multimodal, multipronged, mutation, MuVaxx, nAb, Najjam, nanomolar, nanoparticle, nasal, nasopharynx, NBS, nephrotic, neuraxially, neuropathy, neutralizing, nil, node, nonsteroidal, Novavax, Nuclear, nucleated, nucleic, nucleocapsid, NuVasive, ocular, Oishi, OPA, opposed, outbreak, outpatient, paired, Pakistan, pandemic, pediatric, perception, phagocytic, pharmacodynamic, phosphate, pioneered, placebo, plagued, plasmid, plc, pleated, pleural, predecessor, premature, priming, prioritization, prioritize, proactive, procurement, prolonged, proof, propriety, PSC, Pulsar, Punjab, pursuit, push, quickly, reaction, recession, reestablishing, Regeneron, reinfection, reinstated, reluctant, reopen, reopened, Republic, rescue, respiratory, resume, revoke, revolving, rich, RNA, Rochester, Sage, saliva, sample, Sangamo, SC, Seprehvec, SeprehvecTM, sera, serine, serological, ServiceSource, shallow, SHIELDTM, shut, shutdown, Silence, simultaneously, SLN, SmartPharm, social, sodium, Southern, SP, spike, splenic, spread, SREV, stable, storm, strength, stromal, sumatriptan, superfamily, susceptible, Svetomir, SVP, swab, Syrian, syringe, tag, team, temporarily, theoretically, thrombocytopenia, throughput, tied, tightening, TKI, TM, TRAC, transient, trauma, trend, tubulin, ubiquitously, UK, ultrapotent, umbilical, unexpectedly, vaccinated, vaccination, vaccine, vascular, Vcinity, vector, Veracyte, Vir, Wasa, Western, widespread, withheld, worse, WT, Wuhan, Xencor, young, Zenoff
Removed: accelerating, accredited, accrue, aimed, Appendix, ATM, biobetter, blockade, Bridge, call, Cambridge, campaigning, canceled, cancelled, CEA, Chan, characteristic, coincided, concluding, Conversely, converted, copolymeric, CRADA, cumulatively, CynviloqTM, damaging, DARZALEX, depart, designee, diblock, diversity, eradicated, escrow, exchanged, explain, FBR, Fifty, flat, franchise, funded, hematology, highlight, industrial, infect, institution, Janssen, Jersey, killed, killing, leasing, leaving, Mabtech, manageable, measure, micellar, MLV, multiply, Negev, oncologic, Oxford, partially, practical, prepare, preparing, prespecified, ramp, ratable, reacquisition, reassessed, remediate, remediation, representing, Riley, selectively, shareholder, Silicon, Society, SPI, tangible, tolerable, transform, translational, transparent, treatable, Trump, unamortized, unchanged, unexercised, unveiled, Valley, VWAP, xenograft